Risk factor analysis in clinical isolates of ESBL and MBL (Including NDM-1) producing escherichia coli and klebsiella species in a tertiary care hospital

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 11, 2015, Pages DC08-DC13

  Kumar, Manoj ^a   Dutta, Renu ^b   Saxena, Sonal ^b   Singhal, Smita ^c  

^a HINDU RAO HOSPITAL   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

^c MSD Pharmaceutical Private Limited   (India)

Author keywords

Antimicrobial susceptibility; Antimicrobial therapy; E test; Polymerase chain reaction

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GATIFLOXACIN; IMIPENEM; METALLO BETA LACTAMASE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; NORFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; COMMUNITY ACQUIRED INFECTION; DIABETES MELLITUS; DISK DIFFUSION; ESCHERICHIA COLI; FEMALE; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFANT; INFECTION RISK; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NEUROLOGIC DISEASE; NEWBORN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR; URINARY CATHETER; VERY ELDERLY;

EID: 84946549463     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/15672.6766     Document Type: Article

References (21)

1. Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit Care Clin. 2006,22(2):291-311.
2. Davis KA. Ventilator-associated pneumonia: a review. J Intensive Care Med. 2006,21(4):211-26.
3. National Institute of Allergy and Infectious Diseases. The problem of antimicrobial resistance. April 2006. http://www.niaid.nih.gov/factsheets/antimicro.htm.
4. Nordmann P, Cuzon G, Nass T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009,9:228-36.
5. Collee JQ, Marr W. Culture of bacteria. In: Collee JG, Marmion BP, Fraser AG, Simmons A, editors. Mackie and McCartney’s Practical Medical Microbiology 14th ed. New York: Churchill Livingstone, 1996:113-29.
6. Collee JG, Miles RS, Watt B. Tests for identification of bacteria. In: Collee JG, Marmion BP, Fraser AG, Simmons A, editors. Mackie and McCartney’s Practical Medical Microbiology 14th ed. New York: Churchill Livingstone, 1996: 131-49.
7. Clinical and Laboratory Standards Institute (CLSI) (2011). Performance Standards for Antimicrobial Susceptibility Testing, Twenty-First Informational Supplement. M100-S21. Vol. 31 No. 1.
8. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001,48(Suppl S1):5-16.
9. Livermore DM, Brown DFJ. Detection of p-lactamase-mediated resistance. J Antimicrob Chemother. 2001,48(Suppl S1):59-64.
10. Behera B, Mathur P, Das A, Kapil A, Sharma V An evaluation of four different phenotypic techniques for detection of metallo-p-lactamase producing Pseudomonas aeruginosa. Ind J Med Microbiol. 2008,26(3):233-37.
11. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004,42(3):1089-94.
12. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended- spectrum p-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001,32:1162-71.
13. Shobha KL, Rao GS, Rao S, Sreeja CK. Prevalence of extended spectrum beta- lactamases in urinary isolates of Escherichia coli, Klebsiella and Citrobacter species and their antimicrobial susceptibility pattern in a tertiary care hospital. Indmedica - Ind J Pract Doctor. 2007,3(6).
14. Chaudhuri BN, Rodrigues C, Balaji V, Iyer R, Sekar U, Wattal C, et al. Incidence of ESBL producers amongst gram-negative bacilli isolated from intra-abdominal infections across India (based on SMART study, 2007 data). J Assoc Physicians India. 2011,59:287-92.
15. Jitsurong S, Yodsawat J. Prevalence of extended-spectrum beta-lactamases (ESBLs) produced in blood isolates of gram-negative bacteria in a teaching hospital in southern Thailand. Southeast Asian J Trop Med Public Health. 2006,37:131-35.
16. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi metallo-p-lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J Ass Physicians India. 2010,58:147-50.
17. Chakraborty D, Basu S, Das S. A study on infections caused by metallo-p- lactamase producing gram negative bacteria in intensive care unit patients. Am J Infect Dis. 2010,6(2):34-39.
18. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiology study. Lancet Infect Dis. 2010,10(9):597-602.
19. Marra AR, Wey SB, Castelo A, Gales AC, Cal RGR, Filho JRC, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended- spectrum p-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis. 2006,6:24.
20. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended-spectrum beta- lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res. 2002,115:153-57.
21. Cagnacci S, Gualco L, Roveta S, Mannelli S, Borgianni L, Docquier J, et al. Bloodstream infections caused by multi-drug resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-p-lactamase: first Italian outbreak. J Antimicrob Chemother. 2008,61(2):296-300.